Abstracts tagged "body mass and etanercept"

Abstract Number: 1513 • 2018 ACR/ARHP Annual Meeting
Efficacy of Etanercept By Body Mass Index in Women and Men with Rheumatoid Arthritis: A Post Hoc Analysis of Three Randomized Trials
Rieke Alten¹, Eduardo Mysler², Amy Wajdula³, Heather Jones⁴, Ronald Pedersen⁴ and Lisa Marshall⁴, ¹Schlosspark-Klinik University Medicine, Berlin, Germany, ²Organización Médica de Investigación, Buenos Aires, Argentina, ³Lehigh University, Devon, PA, ⁴Pfizer, Collegeville, PA
Background/Purpose: In patients with RA treated with TNF-α inhibitors, a higher BMI has been associated with lower odds of achieving disease remission. We evaluated the…
Abstract Number: 362 • 2012 ACR/ARHP Annual Meeting
Response to Etanercept, but Not Infliximab or Adalimumab, Is Inversely Associated with Body Mass Index
James R. Maxwell¹, Darren Plant², Anne Barton², Kimme L. Hyrich³, Ann W. Morgan⁴, John Isaacs⁵ and Anthony G. Wilson⁶, ¹Infection & Immunity, University of Sheffield, Sheffield, United Kingdom, ²Arthritis Research UK Epidemiology Unit, University of Manchester, Manchester, United Kingdom, ³Centre for Musculoskeletal Research, University of Manchester, Manchester, United Kingdom, ⁴Section of Musculoskeletal Disease, NIHR-Leeds Musculoskeletal Biomedical Research Unit and Leeds Institute of Molecular Medicine, University of Leeds, Leeds, United Kingdom, ⁵Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom, ⁶Infection and Immunity, University of Sheffield, Sheffield, United Kingdom
Background/Purpose: Recent studies have demonstrated inverse association between BMI and radiographic severity in patients with Rheumatoid Arthritis (RA). There is also preliminary evidence that body…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].